{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:49:43Z","timestamp":1776232183923,"version":"3.50.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the long-term safety and effectiveness of ixekizumab for axial spondyloarthritis in the real-world setting in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-arm, multicentre, observational study was conducted from 26 May 2020 to 10 March 2023 on adult patients with axial spondyloarthritis who were administered ixekizumab under daily clinical practice in Japan. Baseline patient characteristics were summarized. Adverse events, adverse drug reactions, physician-rated overall improvement, and patient-reported Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores were assessed for 96\u00a0weeks after ixekizumab initiation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 39 enrolled patients, 29 consented to publication and were included in these analyses (n\u2009=\u200921 ankylosing spondylitis; n\u2009=\u20098 non-radiographic axial spondyloarthritis). Sixteen patients (55.2%) were male, with a median (range) age of 52.0 (32.0\u201376.0) years. Fourteen (48.3%) and 4 (13.8%) patients experienced adverse events and adverse drug reactions, respectively, most commonly infections and administration site reactions. No serious adverse events or adverse drug reactions were reported. Across 96\u00a0weeks, physicians rated \u226575.0% patients as showing improvement. BASDAI scores showed trends consistent with improvement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings are consistent with ixekizumab clinical trial data from other countries, showing the long-term safety and effectiveness of ixekizumab in patients with axial spondyloarthritis under routine clinical care in Japan.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/mr\/roaf108","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:06:50Z","timestamp":1762520810000},"page":"439-446","source":"Crossref","is-referenced-by-count":0,"title":["Safety and effectiveness of ixekizumab in Japanese patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis in real-world use: a post-marketing safety study"],"prefix":"10.1093","volume":"36","author":[{"given":"Hideto","family":"Kameda","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University , Tokyo ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayi","family":"Dong","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chie","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Konomi","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumiko","family":"Nishikawa","sequence":"additional","affiliation":[{"name":"Japan Drug Development and Medical Affairs, Eli Lilly Japan K.K. , Kobe ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Tomita","sequence":"additional","affiliation":[{"name":"Graduate School of Health Science, Morinomiya University of Medical Sciences , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2026041500565483300_ref1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)31591-4","article-title":"Axial spondyloarthritis","volume":"390","author":"Sieper","year":"2017","journal-title":"Lancet."},{"key":"2026041500565483300_ref2","doi-asserted-by":"crossref","first-page":"e004218","DOI":"10.1136\/rmdopen-2024-004218","article-title":"Factors associated with poor mental health in patients with axial spondyloarthritis: Results from the International Map of Axial Spondyloarthritis (IMAS)","volume":"10","author":"Garrido-Cumbrera","year":"2024","journal-title":"RMD Open"},{"key":"2026041500565483300_ref3","doi-asserted-by":"crossref","first-page":"e003504","DOI":"10.1136\/rmdopen-2023-003504","article-title":"International Map of Axial Spondyloarthritis (IMAS): Results from the perspective of 5557 patients from 27 countries around the globe","volume":"10","author":"Garrido-Cumbrera","year":"2024","journal-title":"RMD Open"},{"key":"2026041500565483300_ref4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.berh.2015.04.002","article-title":"The impact of ankylosing spondylitis\/axial spondyloarthritis on work productivity","volume":"29","author":"Martindale","year":"2015","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2026041500565483300_ref5","first-page":"S136","article-title":"A systematic literature review of the economic impact of ankylosing spondylitis","volume":"30","author":"Palla","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"2026041500565483300_ref6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/acr.24482","article-title":"Improvement of functioning and health with ixekizumab in the treatment of active nonradiographic axial spondyloarthritis in a 52-week, randomized, controlled trial","volume":"74","author":"Walsh","year":"2022","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026041500565483300_ref7","doi-asserted-by":"crossref","first-page":"j839","DOI":"10.1136\/bmj.j839","article-title":"Spondyloarthritis: Diagnosis and management: Summary of NICE guidance","volume":"356","author":"McAllister","year":"2017","journal-title":"BMJ."},{"key":"2026041500565483300_ref8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11926-022-01068-4","article-title":"Axial spondyloarthritis in Japan","volume":"24","author":"Kameda","year":"2022","journal-title":"Curr Rheumatol Rep"},{"key":"2026041500565483300_ref9","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1093\/mr\/roab096","article-title":"A nationwide questionnaire survey on the prevalence of ankylosing spondylitis and non-radiographic axial spondyloarthritis in Japan","volume":"32","author":"Matsubara","year":"2022","journal-title":"Mod Rheumatol"},{"key":"2026041500565483300_ref10","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1080\/1744666X.2021.1970534","article-title":"Ixekizumab: An IL-17A inhibitor for the treatment of axial spondylarthritis","volume":"17","author":"Harrison","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"key":"2026041500565483300_ref11","doi-asserted-by":"crossref","first-page":"479","DOI":"10.5483\/BMBRep.2013.46.10.141","article-title":"The role of interleukin-17 in bone metabolism and inflammatory skeletal diseases","volume":"46","author":"Lee","year":"2013","journal-title":"BMB Rep"},{"key":"2026041500565483300_ref12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"2026041500565483300_ref13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/art.40753","article-title":"Efficacy and safety of ixekizumab in the treatment of radiographic axial spondyloarthritis: Sixteen-week results from a phase III randomized, double-blind, placebo-controlled trial in patients with prior inadequate response to or intolerance of tumor necrosis factor inhibitors","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2026041500565483300_ref14","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","article-title":"Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): A randomised, placebo-controlled trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet."},{"key":"2026041500565483300_ref15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","article-title":"COAST-V and COAST-W study groups. Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)","volume":"79","author":"Dougados","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026041500565483300_ref16","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","article-title":"COAST-V study group.: Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial","volume":"392","author":"Heijde","year":"2018","journal-title":"Lancet."},{"key":"2026041500565483300_ref17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.immuni.2019.03.017","article-title":"Cytokine networks in the pathophysiology of inflammatory bowel disease","volume":"50","author":"Friedrich","year":"2019","journal-title":"Immunity."},{"key":"2026041500565483300_ref18","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.immuni.2015.09.003","article-title":"Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability","volume":"43","author":"Lee","year":"2015","journal-title":"Immunity."},{"key":"2026041500565483300_ref19","first-page":"2018","author":"Ministerial Ordinance on Good Post-marketing Study Practice for Drugs","year":"2004"},{"key":"2026041500565483300_ref20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"2026041500565483300_ref21","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: The bath ankylosing spondylitis disease activity index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2026041500565483300_ref22","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1136\/ard.2008.104018","article-title":"The assessment of SpondyloArthritis international society (ASAS) handbook: A guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026041500565483300_ref23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13075-023-03257-7","article-title":"Long-term safety of ixekizumab in adults with psoriasis, psoriatic arthritis, or axial spondyloarthritis: A post-hoc analysis of final safety data from 25 randomized clinical trials","volume":"26","author":"Deodhar","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"2026041500565483300_ref24","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1007\/s12325-022-02126-0","article-title":"Ixekizumab citrate-free formulation: Results from two clinical trials","volume":"39","author":"Chabra","year":"2022","journal-title":"Adv Ther"},{"key":"2026041500565483300_ref25","doi-asserted-by":"crossref","first-page":"e70081","DOI":"10.1111\/myc.70081","article-title":"Biologic therapy and superficial fungal infection risk in moderate-to-severe psoriasis: A meta-snalysis","volume":"68","author":"Liu","year":"2025","journal-title":"Mycoses."},{"key":"2026041500565483300_ref26","doi-asserted-by":"crossref","first-page":"rkae018","DOI":"10.1093\/rap\/rkae018","article-title":"Real-world experience of IL-17Ai drug survival in a large cohort of axial spondyloarthritis and psoriatic arthritis","volume":"8","author":"Weddell","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"2026041500565483300_ref27","first-page":"139","article-title":"Report of the Japanese central bone marrow data center","author":"Tanaka","year":"1996","journal-title":"Clin Transpl"},{"key":"2026041500565483300_ref28","doi-asserted-by":"crossref","first-page":"e001752","DOI":"10.1136\/rmdopen-2021-001752","article-title":"Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: Results of the cross-sectional ASAS-COMOSPA study","volume":"7","author":"Kishimoto","year":"2021","journal-title":"RMD Open"},{"key":"2026041500565483300_ref29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.berh.2006.03.010","article-title":"Ankylosing spondylitis and bowel disease","volume":"20","author":"Rudwaleit","year":"2006","journal-title":"Best Pract Res Clin Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roaf108\/65240881\/roaf108.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/439\/65240881\/roaf108.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/3\/439\/65240881\/roaf108.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:57:00Z","timestamp":1776229020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/3\/439\/8316755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":29,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,11,7]]},"published-print":{"date-parts":[[2026,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roaf108","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2025,11,7]]}}}